Results 31 to 40 of about 752,560 (269)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer

BMC Cancer, 2023
Objective Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or Calmette-Guerin (BCG) for no more than one
Jian-Xin Chen, Wen-Ting Huang, Qing-Yun Zhang, Cheng-En Deng, Jue-ling Wei, Yuan-Liang Xie, Rui Lin, Guan-Zheng Feng, Guang-Lin Yang, Jun Long, Hao-Yuan Lu, Zeng-nan Mo   +11 more
doaj   +1 more source

Targeting EZH2 reverses thyroid cell dedifferentiation and enhances iodide uptake in anaplastic thyroid cancer

FEBS Letters, EarlyView.
Anaplastic thyroid cancer (ATC) lacks iodide uptake ability due to MAPK activation increasing the expression of the histone methyltransferase EZH2, which represses thyroid differentiation genes (TDGs) such as the sodium iodide symporter (NIS). Dual inhibition of MAPK (U0126) and EZH2 (EPZ6438/Tazemetostat) reverses this mechanism, thus restoring TDG ...
Diego Claro de Mello, Marcella Maringolo Cristovão, Guilherme Henrique, Vinicius Gonçalves Rodrigues, Caroline Serrano‐Nascimento, Edna Teruko Kimura, Cesar Seigi Fuziwara   +6 more
wiley   +1 more source

Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response

Scientific Reports, 2017
Maintaining dendritic cells (DC) in a state of dysfunction represents a key mechanism by which tumour cells evade recognition and elimination by the immune system. Limited knowledge about the intracellular mediators of DC dysfunction restricts success of
Klara Soukup, Angela Halfmann, Barbara Dillinger, Fiona Poyer, Katharina Martin, Bernadette Blauensteiner, Maximilian Kauer, Mario Kuttke, Gernot Schabbauer, Alexander M. Dohnal   +9 more
doaj   +1 more source

Antibody–Drug Conjugates for Cancer Therapy

Molecules, 2020
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Umbreen Hafeez, Sagun Parakh, Hui K. Gan, Andrew M. Scott   +3 more
doaj   +1 more source

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

Expression level and clinical significance of NBAT-1 in human cancers: a systematic review and meta-analysis

BMC Cancer
Purpose There is an aberrant expression of NBAT-1 in various human cancers, which was proven to limit the proliferation, invasion, and metastasis of tumour cells via multiple approaches. Most existing research focuses on sample size and discrete outcomes.
Yang Yu, Kedi Fan, Tingting Ni, Xun Lei Zhang, Xiaoqin Su, Lei Yang   +5 more
doaj   +1 more source

Isolation and Immortalization of Fibroblasts from Different Tumoral Stages

Bio-Protocol, 2014
Tumour microenvironment and cancer-associated fibroblasts in particular exhibit tumour promoting abilities that are not present in their normal counterparts (Calvo et al., 2013; Hanahan and Coussens, 2012).
Fernando Calvo, Steven Hooper, Erik Sahai   +2 more
doaj   +1 more source

Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma

Pharmaceuticals, 2020
Epidermal growth factor receptor (EGFR) is highly overexpressed in malignant mesothelioma (MM). MAb806 is a novel anti-EGFR antibody that selectively targets a tumor-selective epitope. MAb806-derived antibody drug conjugates (ADCs), ABT-414, ABBV-221 and
Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K. Gan, Diana Cao, Ingrid J. G. Burvenich, Angela Rigopoulos, Edward B. Reilly, Thomas John, Andrew M. Scott   +10 more
doaj   +1 more source

The zinc finger domains of PARP‐1 are selectively and potently inhibited by the Au(I)‐based drugs sodium aurothiomalate and aurothioglucose

FEBS Letters, EarlyView.
PARP‐1 is a key enzyme in the DNA damage response, and its inhibition induces cancer cell death via synthetic lethality. Au(I)‐based drugs, such as aurothioglucose and sodium aurothiomalate, block PARP‐1's DNA‐dependent activity by targeting its zinc finger domains.
Uliana Bashtanova, Melinda Jane Duer
wiley   +1 more source

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source